- Home
- SCOR vs CMMB Comparison
SCOR vs CMMB Comparison
Compare SCOR & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCOR
- CMMB
- Stock Information
- Founded
- SCOR 1999
- CMMB 2004
- Country
- SCOR United States
- CMMB Israel
- Employees
- SCOR N/A
- CMMB N/A
- Industry
- SCOR Business Services
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- SCOR Consumer Discretionary
- CMMB Health Care
- Exchange
- SCOR Nasdaq
- CMMB Nasdaq
- Market Cap
- SCOR 25.6M
- CMMB 23.0M
- IPO Year
- SCOR 2007
- CMMB N/A
- Fundamental
- Price
- SCOR $4.88
- CMMB $1.21
- Analyst Decision
- SCOR Buy
- CMMB Strong Buy
- Analyst Count
- SCOR 2
- CMMB 2
- Target Price
- SCOR $10.75
- CMMB $9.00
- AVG Volume (30 Days)
- SCOR 12.5K
- CMMB 89.3K
- Earning Date
- SCOR 05-06-2025
- CMMB 05-27-2025
- Dividend Yield
- SCOR N/A
- CMMB N/A
- EPS Growth
- SCOR N/A
- CMMB N/A
- EPS
- SCOR N/A
- CMMB N/A
- Revenue
- SCOR $354,961,000.00
- CMMB N/A
- Revenue This Year
- SCOR $4.17
- CMMB N/A
- Revenue Next Year
- SCOR $2.74
- CMMB N/A
- P/E Ratio
- SCOR N/A
- CMMB N/A
- Revenue Growth
- SCOR N/A
- CMMB N/A
- 52 Week Low
- SCOR $4.59
- CMMB $0.60
- 52 Week High
- SCOR $15.69
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- SCOR 41.84
- CMMB 46.51
- Support Level
- SCOR $4.54
- CMMB $1.15
- Resistance Level
- SCOR $5.37
- CMMB $1.31
- Average True Range (ATR)
- SCOR 0.41
- CMMB 0.09
- MACD
- SCOR 0.03
- CMMB -0.00
- Stochastic Oscillator
- SCOR 26.98
- CMMB 22.58
About SCOR comScore Inc.
comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each across media platforms. The platforms it measures include televisions, mobile devices, computers, tablets, CTV devices, and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada, and other regions. It provides solutions for the automotive, digital media, financial services, pharmaceutical, retail, technology, travel, and other industries.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.